Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients.

@article{Larriba2010PharmacogeneticsOI,
  title={Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients.},
  author={Juli{\'a}n M Larriba and Nora Imperiali and Rosana Groppa and Cora Giordani and S Algranatti and Mar{\'i}a Ana Redal},
  journal={Transplantation proceedings},
  year={2010},
  volume={42 1},
  pages={257-9}
}
The tacrolimus is metabolized primarily by CYP3A5, a member of the single nucleotide polymorphism family. It shows cytochrome P450 (SNP) in intron 3, which consists of a change of base, G for A, producing a stop codon. The result is a nonfunctional protein (allele *3). Allele *1 is the wild type. The patients that show the allelic variant *3 in homozygosis (G/G) are slow metabolizers of the immunosuppressant, increasing its concentration in blood. In contrast, heterozygote A/G alleles *1/*3 are… CONTINUE READING